1-acyl-4-benzyl-2,5-transdimethyl-piperazine CCR1 antagonists.
Two applications claim 1-acyl-4-benzyl-2,5-dimethylpiperazine derivatives as CCR1 antagonists useful in the treatment of inflammatory diseases. The two applications respectively claim compounds in which the acyl groups are 2-heteroaryl or cinnamoyl (and certain heterocyclic analogues thereof). Both applications describe compounds with good receptor affinity and good in vivo pharmacokinetic properties, displaying a superior profile relative to closely related prior art compounds.